PERTH, Australia – Australian stem cell therapy company Mesoblast Ltd. said its allogeneic mesenchymal precursor cell therapy showed an overall survival rate of 75 percent compared to an expected 30 percent survival rate in its pediatric phase III trial in acute graft-vs.-host disease (aGVHD) at 100 days.